Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.
Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, Zikaras K, Smalley M, Ross M, Tanyi JL, Ghafoor A, Shah NN, Saboury B, Cao L, Quintás-Cardama A, Hong D. Hassan R, et al. Among authors: quintas cardama a. Nat Med. 2023 Aug;29(8):2099-2109. doi: 10.1038/s41591-023-02452-y. Epub 2023 Jul 27. Nat Med. 2023. PMID: 37501016 Free PMC article. Clinical Trial.
GPRC5D-Targeted CAR T Cells for Myeloma.
Quintás-Cardama A. Quintás-Cardama A. N Engl J Med. 2022 Dec 15;387(24):2295-2296. doi: 10.1056/NEJMc2213985. N Engl J Med. 2022. PMID: 36516097 No abstract available.
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, Ricafort R, Heenen D, Bassan A, Berntgen M, Bird N, Bleickardt E, Bouchkouj N, Bross P, Brownstein C, Cohen SB, de Rojas T, Ehrlich L, Fox E, Gottschalk S, Hanssens L, Hawkins DS, Horak ID, Taylor DH, Johnson C, Karres D, Ligas F, Ludwinski D, Mamonkin M, Marshall L, Masouleh BK, Matloub Y, Maude S, McDonough J, Minard-Colin V, Norga K, Nysom K, Pappo A, Pearce L, Pieters R, Pule M, Quintás-Cardama A, Richardson N, Schüßler-Lenz M, Scobie N, Sersch MA, Smith MA, Sterba J, Tasian SK, Weigel B, Weiner SL, Zwaan CM, Lesa G, Vassal G. Pearson AD, et al. Among authors: quintas cardama a. Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25. Eur J Cancer. 2022. PMID: 34840026 Free article. Review.
Idecabtagene Vicleucel in Relapsed Myeloma.
Quintás-Cardama A. Quintás-Cardama A. N Engl J Med. 2021 Jun 17;384(24):2357. doi: 10.1056/NEJMc2105069. N Engl J Med. 2021. PMID: 34133870 No abstract available.
CAR-Transduced Natural Killer Cells.
Quintás-Cardama A. Quintás-Cardama A. N Engl J Med. 2020 May 7;382(19):1866. doi: 10.1056/NEJMc2004226. N Engl J Med. 2020. PMID: 32374975 No abstract available.
Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma.
Quintás-Cardama A. Quintás-Cardama A. N Engl J Med. 2019 Jul 18;381(3):e6. doi: 10.1056/NEJMc1907520. N Engl J Med. 2019. PMID: 31314981 No abstract available.
Synthetic T cell receptor-based lymphocytes for cancer therapy.
Getts D, Hofmeister R, Quintás-Cardama A. Getts D, et al. Among authors: quintas cardama a. Adv Drug Deliv Rev. 2019 Feb 15;141:47-54. doi: 10.1016/j.addr.2019.04.002. Epub 2019 Apr 12. Adv Drug Deliv Rev. 2019. PMID: 30981835 Review.
What CAR Will Win the CD19 Race?
Quintás-Cardama A. Quintás-Cardama A. Mol Cancer Ther. 2019 Mar;18(3):498-506. doi: 10.1158/1535-7163.MCT-18-1070. Mol Cancer Ther. 2019. PMID: 30824581 Review.
208 results